Richard Alistair Stewart
Known title: Executive ChairmanCIK: 0001713369
Richard Alistair Stewart's purchase track record
Richard Alistair Stewart has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/17/2025 | ACHV | $29K | +6.5% | +4.5% | +16.6% |
| 3/4/2024 | ACHV | $46K | +17.9% | -2.0% | +7.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ACHV | ▼ Sell | Open Market | 20,626 | $175K | 8/19/2026 | View on chart |
| ACHV | ▲ Buy | Option Exercise | 297,500 | $0 | 9/18/2025 | View on chart |
| ACHV | ▼ Sell | Open Market | 129,501 | $378K | 9/18/2025 | View on chart |
| ACHV | ▲ Buy | Open Market | 10,000 | $29K | 3/17/2025 | View on chart |
| ACHV | ▼ Sell | Tax Withholding | 10,125 | $46K | 4/19/2024 | View on chart |
| ACHV | ▲ Buy | Option Exercise | 22,500 | $0 | 4/19/2024 | View on chart |
| ACHV | ▲ Buy | Open Market | 10,000 | $46K | 3/4/2024 | View on chart |
| ACHV | ▲ Buy | Option Exercise | 5,000 | $0 | 4/28/2023 | View on chart |
| ACHV | ▼ Sell | Tax Withholding | 2,250 | $19K | 4/28/2023 | View on chart |
| ACHV | ▲ Buy | Option Exercise | 22,500 | $0 | 4/21/2023 | View on chart |
| ACHV | ▼ Sell | Tax Withholding | 10,125 | $69K | 4/21/2023 | View on chart |
| ACHV | ▲ Buy | Option Exercise | 5,000 | $0 | 4/28/2022 | View on chart |
| ACHV | ▼ Sell | Tax Withholding | 2,250 | $17K | 4/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
ACHV: Downgrade noted, thesis intact; funding backs reset
Two recent SeekingAlpha articles discuss Achieve Life Sciences. One notes a rating downgrade but says the clinical thesis remains intact and the overall setup is still constructive. The other reports that the company has obtained funding to reset its manufacturing operations, indicating progress on the production side while keeping the clinical outlook unchanged.
ACHV: Downgrade noted, thesis intact; funding backs reset. Two recent SeekingAlpha articles discuss Achieve Life Sciences. One notes a rating downgrade but says the clinical thesis remains intact and the overall setup is still constructive. The other reports that the company has obtained funding to reset its manufacturing operations, indicating progress on the production side while keeping the clinical outlook unchanged.